Form 4: Amgen Director Ellen Kullman Reports Acquisition of 719 Shares of Common Stock

Director Ellen Kullman reports acquiring 719 shares of Amgen common stock on May 31, 2024, through the vesting of restricted stock units.

Summary

• On May 31, 2024, Ellen Jamison Kullman, a director of Amgen Inc., acquired 719 shares of common stock.
• The acquisition was through the vesting of Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The RSUs vested immediately and are payable in shares of Amgen's common stock on a one-to-one basis.
• Kullman directly owns 12,299.9807 shares of Amgen common stock following the transaction, which includes 1,359 Dividend Equivalents (DEs).
• The DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vested RSUs are paid in shares of the Company's common stock on a one-to-one basis and may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

Industry Context

Director stock ownership is a common practice in publicly traded companies and is often viewed as aligning the interests of management with those of shareholders. This Form 4 filing is a routine disclosure required by the SEC.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.

Key Dates